AstraZeneca Pharma India Limited share price

AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and trades in pharmaceutical products in India and internationally. It provides medicines for cancers, including pancreatic cancer, certain blood cancers, and cancers within breast, lung, ovary, and prostate; rare diseases; and cardiovascular, renal and metabolism, and respiratory and immunology, as well as diabetes. The company serves distributors, hospitals, and government institutions. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.Read more

Website NSE हिंदी में BSE

HealthcareDrug Manufacturers - Specialty & GenericNSE: ASTRAZENISIN INE203A01020

16 Oct 2026, 3:29 PM IST₹5,970.50▲ 33.50 (0.56%)

Market Cap₹ 14,926 Cr.
Current Price₹ 5,970.50
High / Low₹ 9,850 / 5,640
Stock P/E88.0
Book Value₹ 349
Dividend Yield0.61 %
ROCE25.5 %
ROE22.80 %
Face Value₹ 2.0

More figures (10)

EPS (TTM)₹ 67.85
Price / Book17.10
OPM10.3 %
Debt / Equity0.13
Sales growth (5Y)22.8 %
Profit growth (5Y)15.0 %
Promoter holding81.5 %
EV / EBITDA64.7
Beta0.23
All-time high₹ 10,691

Price chart

Price on NSE 50 DMA 200 DMA Volume

Returns	1M	3M	6M	YTD	1Y	3Y CAGR	5Y CAGR
ASTRAZEN	-10.93%	-26.16%	-29.99%	-33.87%	-34.40%	+8.34%	+13.96%
Nifty 50	-0.31%	-3.85%	-4.34%	-11.42%	-9.53%	+5.46%	+4.76%

Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.

Quick take

AstraZeneca Pharma India Limited is in the Drug Manufacturers - Specialty & Generic industry (Healthcare), with a market value of ₹14,926 crore.
It trades at 88.0 times its last 12 months' earnings and 17.1 times book value.
Revenue grew 22.8% a year over the last 5 years, profit 15.0% a year.
Return on equity was 22.8% and return on capital employed 25.5% in the latest year.
Debt was 0.13 times shareholders' equity.
The share price is 39.4% below its 52-week high and down 34.4% over one year.
Promoters and insiders hold about 81.5%; institutions about 9.2%.

Pros

Strong return on equity: 21.1% on average over the last 3 years.
Sales have grown 22.8% a year over the last 5 years.
Trades at 88.0 times earnings, below its 3-year median of 124.1.
Borrowings are moderate at 0.13 times shareholders' equity.
Pays a healthy dividend: about 43% of profit last year.

Cons

Latest quarter (Jun 2026): profit fell 32% from a year ago.
Trades at 17.1 times its book value.

Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.

AI analysis

Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.

About AstraZeneca Pharma India Limited

Employees: 600
Head office: Bengaluru

HealthcareDrug Manufacturers - Specialty & Generic

S.No.	Company	CMP ₹	P/E	Mar Cap ₹ Cr	Div Yld %	NP Qtr ₹ Cr	Qtr Profit Var %	Sales Qtr ₹ Cr	Qtr Sales Var %	ROCE %	ROE %	P/B	OPM %	Debt / Eq	Prom. Hold. %	Sales ₹ Cr	Sales Var 3Yrs %
1.	AstraZeneca Pharma India	5,970.50	88.0	14,926	0.61	38	-32.06	683	29.73	25.5	22.8	17.10	10.3	0.13	81.48	2,276	22.8
2.	Sun Pharmaceutical Industries	1,758.80	34.9	4,21,995	0.91	2,895	34.65	15,184	18.48	17.9	14.7	5.05	23.4	0.06	55.61	58,220	10.4
3.	Divi's Laboratories	9,144.50	83.0	2,42,758	0.33	902	36.25	3,080	19.15	19.0	16.2	14.48	28.4	0.00	52.00	10,476	11.0
4.	Torrent Pharmaceuticals	4,558.90	72.8	1,73,406	0.83	566	3.28	4,835	54.57	9.1	27.1	18.39	25.0	1.79	63.18	13,753	13.3
5.	Zydus Lifesciences	1,123.00	25.0	1,12,020	0.09	940	-19.74	7,802	24.03	19.0	19.7	4.17	21.7	0.46	75.18	26,720	16.5
6.	Laurus Labs	2,060.10	101.8	1,11,310	0.12	362	123.94	2,026	29.10	19.5	18.2	20.98	19.4	0.48	32.03	6,813	3.8
7.	Cipla	1,325.10	31.8	1,07,051	0.98	789	-35.42	7,077	7.26	14.9	11.8	3.11	17.5	0.02	31.13	27,712	7.2
8.	Dr. Reddy's Laboratories	1,233.00	31.0	1,02,707	0.66	444	-68.72	8,071	-5.56	14.2	12.1	2.68	14.9	0.21	30.14	33,593	11.0
9.	Aurobindo Pharma	1,666.90	26.0	95,910	0.00	1,033	14.29	9,106	8.65	13.5	9.9	2.56	15.6	0.21	54.79	33,385	10.7
10.	Mankind Pharma	2,275.50	46.0	93,988	0.00	568	35.00	4,031	30.89	13.7	12.5	5.76	19.9	0.39	75.39	14,278	17.7
	Median: 31 Co.	1,909.45	34.4	41,599	0.35	679	8.79	5,956	21.59	16.4	16.8	4.98	18.8	0.21	55.20	20,499	13.5

Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.

Quarterly Results

Standalone figures in ₹ crore

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	295	311	306	383	388	408	440	480	526	559	612	579	683
YOY Sales Growth %	27.17%	31.74%	22.41%	34.60%	31.16%	31.16%	43.98%	25.39%	35.81%	37.03%	38.90%	20.42%	29.73%
	228	258	291	334	349	355	363	394	445	484	567	518	634
Material Cost %	37%	39%	48%	56%	59%	55%	56%	54%	56%	58%	60%	68%	65%
Employee Cost %	19%	21%	21%	15%	16%	17%	14%	14%	12%	11%	15%	8%	12%
Other Expenses %	21%	23%	26%	16%	15%	15%	12%	14%	16%	18%	17%	13%	16%
Operating Profit	67	53	15	49	38	53	77	86	81	75	45	61	49
OPM %	23%	17%	5%	13%	10%	13%	17%	18%	15%	13%	7%	11%	7%
	8	8	10	9	8	8	8	16	11	6	5	6	9
Exceptional items		16			-58		-34	-6	-0	-5	1	-1	-0
Interest	0	1	1	-0	0	0	0	1	1	1	1	2	2
Depreciation	4	4	4	4	4	9	9	18	17	3	4	6	5
Profit before tax	71	73	20	54	-15	51	42	78	75	73	47	58	51
	25%	29%	23%	27%		25%	27%	26%	25%	26%	30%	23%	25%
Current tax	17	21	5	16	11	15	12	23	22	19	4	14	11
Deferred tax	0	-0	-0	-1	-14	-2	-1	-3	-3	-0	10	-1	2
	54	52	16	39	-12	38	31	58	56	54	33	45	38
YOY Profit Growth %	167.26%	60.82%	-46.08%	128.57%	-121.89%	-26.62%	95.25%	47.55%		41.09%	5.64%	-22.95%	-32.06%
EPS in Rs	21.54	20.95	6.32	15.79	-4.72	15.37	12.34	23.30	22.33	21.69	13.04	17.95	15.17
Raw filing

Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Latest quarter on the right.

Profit & Loss

Standalone figures in ₹ crore

₹ Cr	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	117	117	728	832	814	806	1,003	1,296	1,716	2,276	2,432
YOY Sales Growth %			523.11%	14.21%	-2.19%	-0.98%	24.50%	29.17%	32.48%	32.59%
	116	116	657	711	678	719	838	1,111	1,462	2,014	2,202
Material Cost %	33%	33%	32%	37%	36%	39%	36%	46%	56%	61%	63%
Employee Cost %	31%	31%	27%	26%	27%	29%	26%	19%	15%	12%	11%
Other Expenses %	36%	36%	31%	23%	20%	22%	22%	21%	14%	16%	16%
Operating Profit	1	1	71	121	135	86	165	184	254	262	230
OPM %	1%	1%	10%	15%	17%	11%	16%	14%	15%	12%	9%
	1	1	16	13	13	15	26	35	41	28	26
Exceptional items							-40	16	-97	-5	-5
Interest				1	1	1	1	1	1	4	6
Depreciation	4	4	15	19	20	17	16	15	40	29	17
Profit before tax	-2	-2	73	114	127	83	134	220	156	252	228
			25%	37%	27%	26%	26%	26%	26%	26%	26%
Current tax	1	1	17	32	35	23	38	54	61	59
Deferred tax	7	7	2	10	-1	-1	-3	4	-20	5
	-10	-10	54	72	93	62	99	162	116	188	170
YOY Profit Growth %				32.64%	29.21%	-33.99%	61.21%	62.66%	-28.34%	62.02%
EPS in Rs	-3.82	-3.82	21.78	28.88	37.32	24.64	39.72	64.60	46.30	75.01	67.85
Dividend Payout %							20%	25%	52%	43%

Compounded Sales Growth

5 Years:: 23%
3 Years:: 31%
TTM:: 31%

Compounded Profit Growth

5 Years:: 15%
3 Years:: 24%
TTM:: -7%

Stock Price CAGR

5 Years:: 14%
3 Years:: 8%
1 Year:: -34%

Return on Equity

4 Years:: 20%
Last Year:: 23%

Financial years ending March; TTM = the last four quarters. Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Dividend payout = dividends paid in the year ÷ net profit.

Balance Sheet

Consolidated figures in ₹ crore, as at 31 March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	5	5	5	5
Reserves	584	707	765	868
Borrowings	7	5	36	111
	389	362	712	1,006
Trade payables	228	197	456	783
Current liabilities	384	357	703	982
Total Liabilities	985	1,078	1,518	1,989
	70	65	64	117
Gross block	181	186	215	185
Accumulated depreciation	111	121	152	67
Goodwill & intangibles		2	1
CWIP	2	1
	913	1,013	1,455	1,872
Inventories	190	228	549	1,027
Trade receivables	108	153	185	214
Cash & equivalents	500	506	536	448
Current assets	835	933	1,342	1,740
Total Assets	985	1,078	1,518	1,989

Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.

Cash Flows

Consolidated figures in ₹ crore, financial years ending March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	58	28	65	-15
Profit for the year	99	162	116	188
Working capital changes	-30	-128	-103	-217
Direct taxes paid	-41	-56	-64	-83
	18	22	31	19
Fixed assets purchased	-9	-11	-2	-4
Fixed assets sold	3	0	1	0
	-24	-44	-66	-92
Interest paid	-1	-1	-1	-4
Dividends paid	-20	-40	-60	-80
Net Cash Flow	52	5	31	-88
Free Cash Flow	50	17	64	-19

Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.

Ratios

Ratio	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
ROE	—	16.9%	24.8%	15.6%	22.8%
ROCE	—	22.4%	30.6%	19.4%	25.5%
Operating margin	—	14.8%	13.2%	12.5%	10.3%
Net margin	—	9.9%	12.5%	6.8%	8.3%
Debt / equity	—	0.01	0.01	0.05	0.13
Current ratio	—	2.18	2.61	1.91	1.77
Debtor days	—	39	43	39	34
Inventory days	—	163	124	200	252
Days payable	—	196	107	166	192
Cash conversion cycle	—	6	60	73	94
Working capital days	—	164	162	136	122

Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.

Shareholding Pattern

Numbers in percentages · as filed with NSE each quarter

Promoters 75.00%
FIIs 2.64%
DIIs 7.09%
Public 15.27%

%	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%
	2.65%	2.74%	2.79%	2.90%	2.93%	2.89%	3.03%	2.74%	2.71%	2.78%	2.68%	2.64%
Foreign portfolio investors (Cat. I)	2.58%	2.65%	2.67%	2.80%	2.83%	2.75%	2.70%	2.63%	2.61%	2.68%	2.58%	2.54%
Foreign portfolio investors (Cat. II)	0.08%	0.08%	0.12%	0.10%	0.09%	0.14%	0.33%	0.11%	0.10%	0.10%	0.10%	0.10%
	2.78%	3.78%	5.01%	5.10%	5.22%	4.65%	4.56%	5.26%	5.56%	5.80%	6.08%	7.09%
Mutual funds	2.75%	3.75%	4.97%	5.05%	5.04%	4.45%	4.33%	5.00%	5.43%	5.66%	6.01%	7.01%
Insurance companies					0.13%	0.16%	0.18%	0.19%	0.05%	0.06%
Alternative investment funds	0.01%	0.02%	0.02%	0.03%	0.03%	0.03%	0.03%	0.06%	0.06%	0.06%	0.06%	0.07%
	19.57%	18.48%	17.20%	17.00%	16.85%	17.46%	17.41%	17.00%	16.73%	16.42%	16.24%	15.27%
Retail (up to ₹2 lakh)	9.10%	8.35%	8.25%	8.22%	8.06%	8.49%	8.51%	7.76%	7.51%	7.70%	7.65%	7.70%
HNIs (above ₹2 lakh)	7.99%	7.99%	6.75%	6.56%	6.56%	6.66%	6.66%	6.63%	6.63%	6.18%	6.11%	5.12%
NRIs	0.35%	0.25%	0.31%	0.32%	0.34%	0.39%	0.40%	0.39%	0.36%	0.35%	0.36%	0.36%
Bodies corporate	1.58%	1.37%	1.33%	1.35%	1.33%	1.36%	1.32%	1.09%	1.15%	1.13%	1.08%	1.05%
IEPF	0.43%	0.42%	0.42%	0.42%	0.42%	0.41%	0.41%	0.40%	0.40%	0.38%	0.37%	0.36%
No. of Shareholders	29,032	29,418	27,169	27,615	27,322	32,466	34,378	32,914	31,551	29,007	29,338	30,408

Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.

Mutual funds & institutions holding AstraZeneca Pharma India

Holder (above 1%)	Stake
NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA SMALL CAP FUND(VARIOUS SCHEMES)Mutual fund · see the fund house	2.90%
Icici Prudential - Various SchemesMutual fund	2.18%
Bandhan - Various SchemesMutual fund	1.50%

As named in the shareholding pattern for Sep 2026 filed with NSE; mutual funds together hold 7.01% of the company. Shareholders below 1% are not named in the filing.

Documents

Announcements

All announcements on NSE →

Annual reports

Credit ratings

Concalls & investor meets

Filings made by the company with NSE; documents open on NSE's website.

Key dates

Ex-dividend date: 31 Jul 2026
Latest quarter: 30 Jun 2026
Financial year end: 31 Mar 2026

Trade with our broking desk

Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.

Open an account How it works

Latest news

In the news

No recent coverage found.

From the company (NSE)

Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.

Questions about AstraZeneca Pharma India Limited

What is the share price of AstraZeneca Pharma India Limited today?

AstraZeneca Pharma India Limited (ASTRAZEN) last traded at ₹5,970.50 on NSE (16 Oct 2026, 3:29 PM IST). Prices may be delayed.

What is the market cap of AstraZeneca Pharma India Limited?

About ₹14,926 crore at the latest price.

What is the P/E ratio of AstraZeneca Pharma India Limited?

About 88.0 times its earnings over the last 12 months.

Is AstraZeneca Pharma India Limited a good investment?

We do not give views on individual shares. Whether any share suits you depends on your goals, time horizon and risk appetite; for long-term goals, a diversified mutual fund is often a simpler way to own shares. Investments in securities markets are subject to market risks.

How can I buy AstraZeneca Pharma India Limited shares?

You need a trading and demat account with a SEBI-registered stock broker. We can help you open one through Parshvanath Investments, an Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539). We provide execution and account service only, not tips or research.

Important. Prices from NSE via Yahoo Finance. Quarterly and annual results, shareholding and documents are taken from the filings the company made with NSE; balance sheet, cash flow and valuation figures are compiled by Yahoo Finance; ratios are computed by us from them. Figures may be delayed or revised. This page is for information only: it is not research, a recommendation or an offer to buy or sell any security. Investments in securities markets are subject to market risks; read all related documents carefully before investing. Plenitude Connect Private Limited is an AMFI-registered Mutual Fund Distributor (ARN-130934); share broking is offered through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539).

Talk to us

Have a question about this topic?

Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.

Get in touch

We typically respond within 2 hours on business days.

Call us

CA Amit Kumar Jain+91 93522 44475 Arihant Jain+91 80056 49698 Poornima Jain+91 92525 44475

Email ussupport@plenitude.co.in

WhatsAppChat with an expert

Visit us5C, Laxmi Colony, Near Bohra Ji Ka Bagh, Opp. Laxmi Mandir Cinema, Tonk Road, Jaipur, Rajasthan 302015

Mon–Sat · 10:00 AM – 7:00 PM IST

In your free consultation

A health check of your current investments
A goal-based plan for retirement, education or a home
Ways to save tax that fit your situation
Clear next steps, with zero pressure to invest

2,000+Investors

₹250 Cr+Client assets

15+ yrsExperience

AMFI Registered Mutual Fund Distributor · ARN-130934

Experts are available Mon–Sat, 10 AM – 7 PM

Book your free wealth consultation

100% free
No obligation
Reply within 2 hours

First name *

Last name *

Email *

Phone *

+91

I'm interested in *

Best day for a call

Preferred time

How can we help? (optional)

Upload your portfolio (optional, get a free expert review)Attach your portfolio statement · PDF, Excel or CSV (e.g. CAS), max 10 MB

I consent to being contacted by Plenitude Connect about financial services. My data will be handled as per the Privacy Policy.

Join 2,000+ investors who plan with Plenitude

Your details are private and never shared.